February 3, 2009 / 9:22 PM / 10 years ago

US panel: Lilly, Daiichi drug benefits trump risks

SILVER SPRING, Md., Feb 3 (Reuters) - Eli Lilly and Co (LLY.N) and Daiichi Sankyo’s (4568.T) experimental anti-clotting drug prasugrel offers benefits that outweigh risks, members of a U.S. advisory panel said on Tuesday.

Prasugrel would offer an alternative to Plavix, now sold by Bristol-Myers Squibb Co (BMY.N) and Sanofi-Aventis SA (SASY.PA) with more than $7 billion in 2007 global sales.

Members of the panel said prasugrel did not need to carry a strong warning about cancer cases seen in a clinical trial. Use of the drug should be discouraged, however, in patients who have had a stroke, panelists said. (Reporting by Lisa Richwine; Editing by Tim Dobbyn)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below